格隆汇1月5日丨嘉必优(688089.SH)公布，截至2025年12月31日，公司通过上海证券交易所交易系统以 集中竞价交易方式累计回购公司股份106.06万股，占公司总股本的比例为0.63%，最高成交价为28.58元/ 股，最低成交价为23.52元/股，累计成交总金额为2792.13万元（不含印花税、交易佣金等交易费用）。 ...

Core Viewpoint - The company announced a share buyback plan through centralized bidding, with an expected amount between 15 million and 30 million yuan, aimed at employee stock incentives [1] Group 1 - The total shares repurchased by the company as of the end of 2025 is 1.0606 million shares, representing 0.63% of the total share capital [1] - The cumulative amount spent on the buyback is 27.9213 million yuan, with the actual repurchase price ranging from 23.52 yuan per share to 28.58 yuan per share [1] - The buyback plan complies with regulations, and the company will implement and disclose progress accordingly [1]

二、募集资金投资项目情况 证券代码：688089 证券简称：嘉必优 公告编号：2025-085 嘉必优生物技术（武汉）股份有限公司关于部分募投项目结项 并将节余募集资金永久补充流动资金及注销相关募集资金专户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意嘉必优生物技术（武汉）股份有限公司首次公开发行股票注册的 批复》（证监许可〔2019〕2338号）同意注册，嘉必优生物技术（武汉）股份有限公司（以下简称"公 司"）公开发行人民币普通股（A股）30,000,000.00股，每股面值为人民币1.00元，发行价格为每股人民 币23.90元。截至2019年12月16日止，公司实际已发行普通股（A股）30,000,000.00股，募集资金总额为 人民币717,000,000.00元，扣除各项发行费用（不含税）人民币68,673,892.62元，实际募集资金净额为人 民币648,326,107.38元。上述资金已于2019年12月16日存入公司募集资金账户中。上述募集资金 ...

证券代码：688089 证券简称：嘉必优 公告编号：2025-085 嘉必优生物技术（武汉）股份有限公司 关于部分募投项目结项并将节余募集资金永久补充流动资 金及注销相关募集资金专户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意嘉必优生物技术（武汉）股份有限公 司首次公开发行股票注册的批复》（证监许可〔2019〕2338 号）同意注册，嘉必 优生物技术（武汉）股份有限公司（以下简称"公司"）公开发行人民币普通股（A 股）30,000,000.00 股，每股面值为人民币 1.00 元，发行价格为每股人民币 23.90 元。截至 2019 年 12 月 16 日止，公司实际已发行普通股（A 股）30,000,000.00 股，募集资金总额为人民币 717,000,000.00 元，扣除各项发行费用（不含税）人 民币 68,673,892.62 元，实际募集资金净额为人民币 648,326,107.38 元。上述资金 已于 2019 年 12 月 16 日存入公司 ...

Core Insights - The article highlights the growth trajectory of Jiabiou, a pioneer in China's food biotechnology sector, emphasizing its strategic alignment with national policies and global technological trends [2][4][42] - Jiabiou has transitioned from a focus on nutritional ingredient development to becoming a key player in supporting the national biomanufacturing strategy, showcasing its commitment to innovation and industry leadership [6][10][42] Financial Performance - Jiabiou's revenue has steadily increased from 312 million yuan in 2019 to an expected 555 million yuan in 2024, reflecting a compound annual growth rate of 12.2% [2][13] - In the first three quarters of 2025, the company achieved revenue of 428 million yuan and a net profit of 129 million yuan, marking a significant year-on-year growth of 54.16% [2][14] Innovation and R&D - The company has invested heavily in R&D, with expenditures reaching 47.9 million yuan in 2024, accounting for 8.6% of its revenue, and a total of 119 million yuan over the past three years [16][17] - Jiabiou has developed a comprehensive technology platform that integrates various biological manufacturing techniques, significantly enhancing production efficiency and product quality [17][27] Global Expansion and Market Position - Jiabiou has established three international-standard production bases and has received key certifications, enabling it to penetrate major global markets [18][19] - The company has formed strategic partnerships with leading distributors, enhancing its market reach and establishing a robust sales network [18][19] Social Responsibility and Industry Impact - Jiabiou actively participates in setting industry standards and promoting sustainable practices, aligning its operations with national carbon reduction goals [20][19] - The company has been recognized for its contributions to the biomanufacturing sector, including being listed among the first batch of "biomanufacturing landmark products" by the Ministry of Industry and Information Technology [5][26] Strategic Positioning - Jiabiou has built a competitive advantage through a combination of policy alignment, technological barriers, and comprehensive supply chain capabilities, positioning itself favorably for future growth [7][9][42] - The company is poised to leverage the opportunities presented by the "14th Five-Year Plan" and the emerging biomanufacturing sector, aiming to become a leader in high-quality development [10][29]

Core Insights - The article highlights the transformation of Jia Bi You Biotechnology (Wuhan) Co., Ltd. from a single nutrient supplier to a synthetic biology platform enterprise over six years since its listing on the Sci-Tech Innovation Board, marking a significant milestone in China's food biotechnology sector [1] Financial Performance - Jia Bi You's revenue has grown from 312 million yuan in 2019 to 555 million yuan in 2024, achieving a compound annual growth rate (CAGR) of 12.2% [2] - In 2025, the company reported a revenue of 428 million yuan and a net profit of 129 million yuan in the first three quarters, reflecting a year-on-year increase of 54.18%, surpassing the total net profit for 2024 [2] - As of December 19, 2025, the company's market capitalization exceeded 3.9 billion yuan, demonstrating significant growth since its initial public offering [2] Product Development and Market Position - The company has expanded its product matrix, achieving over 40% global market share in ARA (Arachidonic Acid) and surpassing 100 million yuan in annual sales for DHA (Docosahexaenoic Acid) [2] - Jia Bi You has developed a diverse product system covering human nutrition, animal nutrition, and personal care, with 114 authorized products for SA (Sialic Acid) [2] - The successful mass production of 2'-fucosyllactose (2'-FL) in 2025 fills a significant gap in China's HMO (Human Milk Oligosaccharides) market [2] Supply Chain and Risk Management - The company has established a fully controllable supply chain, achieving domestic substitution across the entire production process from strain cultivation to fermentation and product application [3] - The second phase of the Wuhan production base has positioned the company among the global leaders in ARA and DHA production capacity [3] - Jia Bi You's products have received international certifications and are exported to over 30 countries, establishing stable partnerships with global giants like Nestlé [3] Research and Development - Jia Bi You maintains a research and development investment of over 8%, with 2024 R&D expenditure reaching 47.9 million yuan, a 24.12% increase year-on-year [4] - The company has developed a full-stack technology loop integrating AI and synthetic biology, breaking foreign monopolies in industrial strains [4] - The establishment of a national pilot platform for microbial fermentation supports the transition from laboratory to production line [4] Industry Standards and Future Strategy - Jia Bi You has actively participated in the formulation of national food safety standards and was selected for the national synthetic biology standardization project research group in 2025 [5] - The company aims to focus on high-end equipment development and advanced molecular layout, targeting the trillion-yuan market outlined in the 14th Five-Year Plan [5] - Future plans include upgrading the pilot platform to a public service hub for bio-manufacturing and deepening global cooperation to expand into European, American, and Southeast Asian markets [5]

Core Insights - The article emphasizes the strategic importance of biomanufacturing, which is projected to create a $30 trillion market, comparable to the significance of chip manufacturing [3] - Biomanufacturing is not merely a replacement for traditional chemical processes but a transformative engine that redefines the underlying logic of industries, impacting the entire supply chain from raw materials to end products [3][4] Company Overview - Jia Bi You has been proactive in the biomanufacturing sector, establishing a robust business model that has evolved significantly since its listing on the STAR Market six years ago [4] - The company reported a revenue increase from 312 million yuan in 2019 to 555 million yuan in 2024, achieving a compound annual growth rate of 12.2% [4] Market Positioning - The implementation of new national standards for infant formula in February 2023 has created a favorable market environment for Jia Bi You, allowing it to efficiently release production capacity [10] - The expiration of DSM's core patents has enabled Jia Bi You to penetrate international markets and establish stable partnerships with major companies like Nestlé and Danone [12] Strategic Growth - Jia Bi You's revenue structure has diversified, with the human nutrition segment's share decreasing from over 95% to around 80%, while the health sector now contributes nearly 20% [13] - The company maintains a high R&D investment rate of 8%-10%, which has supported its innovation and technological advancements [15] Technological Innovation - The company has developed a comprehensive technology system based on synthetic biology, which includes bioinformatics, AI, and other interdisciplinary fields [15][16] - Jia Bi You aims to leverage AI to enhance its research and application processes, creating a specialized biological database to optimize product development and personalized nutrition solutions [18][19] International Expansion - Jia Bi You's international revenue share has increased from less than 10% to nearly 40%, with products now available in over 30 countries [24] - The company adopts a flexible internationalization strategy, focusing on technology cooperation and customized supply rather than aggressive expansion [25] ESG Commitment - Jia Bi You places significant emphasis on ESG practices, having initiated social responsibility reports since 2019 and implementing sustainable practices such as replacing coal boilers with natural gas [27][28] - The company has received recognition for its ESG efforts, highlighting its commitment to environmental, social, and governance standards [30] Future Opportunities - The upcoming "15th Five-Year Plan" presents multiple opportunities for Jia Bi You, including favorable policies for biomanufacturing and increased demand for infant nutrition products [33][34] - The company believes that its internal capabilities and technological advancements will be the primary drivers of growth, rather than external trends [35]

Core Insights - Company has focused on emerging products such as SA (Sialic Acid) and HMOs (Human Milk Oligosaccharides) while maintaining its core product line [1][2] - The company reported a revenue of 430 million yuan for the first three quarters of 2025, a year-on-year increase of 10.56%, and a net profit of 130 million yuan, up 54.18% year-on-year, indicating a significant profit growth outpacing revenue growth [1] - The company aims to expand its market presence in infant formula, animal nutrition, and personal care sectors through a strategy termed "one main and two wings" [1][2] Company Strategy - The company is enhancing its product offerings in the infant formula market by promoting algal oil DHA as a substitute for fish oil DHA and deepening cooperation on HMOs [2] - In the pet nutrition sector, the company employs a strategy of "technology research + brand marketing + supply chain management" to enhance product innovation and competitiveness [3] - In the beauty and personal care sector, the company leverages synthetic biology and innovative technologies to rapidly screen and validate new cosmetic raw materials [3] Market Position - The company is a leader in the microbial synthesis nutrient sector in China, with key products including ARA, DHA, and β-carotene, widely used in infant formula, health foods, animal nutrition, and personal care [1] - The domestic and international milk powder markets continue to provide favorable conditions for the company's stable performance [1] - The approval of HMOs as new raw materials for infant formula by the National Health Commission is expected to accelerate the application of these products in the infant nutrition sector [2]

Group 1 - The company, Jia Bi You, announced that its Q3 2025 earnings briefing is scheduled for December 15, 2025 [1]

证券代码：688089 证券简称：嘉必优 公告编号：2025-084 嘉必优生物技术（武汉）股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （网址：https://roadshow.sseinfo.com/） 嘉必优生物技术（武汉）股份有限公司(以下简称"公司")已于 2025 年 10 月 28 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公 司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 12 月 15 日（星期 一）14:00-15:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交 流。 一、说明会类型 本次投资者说明会以网络文字互动形式召开，公司将针对 2025 年第三季度 经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许 的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2025 年 12 月 15 日（星期一） ...